Previous Close | 2.8800 |
Open | 2.8400 |
Bid | 2.8100 x 200 |
Ask | 2.8400 x 200 |
Day's Range | 2.7900 - 2.9050 |
52 Week Range | 1.9100 - 29.5600 |
Volume | |
Avg. Volume | 1,580,057 |
Market Cap | 86.226M |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.1500 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.64 |
Subscribe to Yahoo Finance Plus to view Fair Value for BTAI
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 3,054,609 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants
BioXcel Therapeutics ( NASDAQ:BTAI ) Full Year 2023 Results Key Financial Results Net loss: US$179.1m (loss widened by...
Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501NEW HAVEN, Conn., March 15, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today reported that the European Patent Office (EPO) granted the Company’s European Patent No. 3,562,486 (the “486 patent”) o